Signaling & Reproductive

PT-141 (Bremelanotide)

SKU NA-030CAS 189691-06-3MW 1025.2
99.84% HPLCThird-party testedRUO · Research use only

$41.98

White to off-white solid. CAS 189691-06-3, MW 1025.2. Reconstitute with bacteriostatic water. Purity 99.84% by RP-HPLC. Research use only — not for human or veterinary use.

Multi-vial pricing
HPLC verifiedPurity confirmed per lot
COA includedLot-specific certificate
Cold-chainShipped 2-8°C with packs
Lot traceableDocumented to dispatch
RUOThis product is sold for laboratory research use only. It is not a drug or supplement and is not for human or veterinary consumption, diagnostic or therapeutic use.
Description

PT-141 (Bremelanotide) is a melanocortin receptor agonist supplied by Nano Aminos strictly as a reference material for in-vitro and laboratory research. It is catalogued under CAS 189691-06-3, molecular formula C50H68N14O10, and a molecular weight of 1025.2 g/mol.

Provided as a lyophilized powder (white to off-white solid), PT-141 (Bremelanotide) is part of the Nano Aminos Signaling & Reproductive research range and is prepared for research use by reconstitution in bacteriostatic water using standard aseptic technique.

Every production lot is characterized by reversed-phase HPLC and mass spectrometry at 99.84% typical HPLC purity and ships with a lot-specific Certificate of Analysis (COA), so identity and purity can be independently confirmed before use. Vials are kept cold and protected from repeated freeze–thaw cycles. PT-141 (Bremelanotide) is available in 10 mg research size.

Related research: browse the full Signaling & Reproductive category or compare SNAP-8 and VIP.

For research use only. Not for human or veterinary use. PT-141 (Bremelanotide) is not a drug, food, or dietary supplement.

Specifications
CompoundPT-141 (Bremelanotide)
ClassificationMelanocortin receptor agonist
CAS number189691-06-3
Molecular formulaC50H68N14O10
Molecular weight1025.2 g/mol
Purity99.84% by RP-HPLC (area %)
Physical formLyophilized powder
AppearanceWhite to off-white solid
ReconstitutionBacteriostatic water
Lab documentation

Each production lot is released against an analytical specification and ships with the corresponding Certificate of Analysis.

Certificate of analysis

PT-141 (Bremelanotide) 10 mg

Lot 407324421
Purity (HPLC-UV)
99.84%
Identity (LC-MS)
Confirmed
Net content
11.24 mg/vial
Appearance
White to off-white lyophilised powder
Method
HPLC-UV with LC-MS confirmation
Reported
28 Jul 2026
Accession
AD-1767-7742-0162
Download image

Opens on this page. Analysis by an independent laboratory. Research use only - not for human or veterinary use.

Storage & handling

Storage. Store lyophilized material at -20°C protected from light and moisture for long-term stability. After reconstitution, keep at 2-8°C and use within the documented in-use window.

Handling. Allow sealed vials to equilibrate to room temperature before opening to limit condensation. Reconstitute with the listed diluent using standard aseptic laboratory technique. Avoid repeated freeze-thaw cycles.

Safety. Handle as a laboratory research chemical. Wear appropriate PPE and follow your institution's chemical-handling and waste-disposal procedures.

Shipping

Dispatch. In-stock orders are processed on business days and shipped with temperature-controlled packaging and gel packs to preserve material integrity in transit.

Tracking. A tracking reference is issued at dispatch. Lab accounts can consolidate shipments and arrange standing orders.

Eligibility. Orders are accepted from researchers, resellers and institutions for laboratory research use only.

Selected research

Literature referencing this compound.

Publications relevant to this molecule, provided for research reference. Inclusion does not imply an approved use or any claim about the products sold here.

Phase 3 RCT
Obstet Gynecol. 2019;134(5):899–908
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Kingsberg SA, Clayton AH, Portman D, et al.
Open-label ext.
Obstet Gynecol. 2019;134(5):909–917
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
Simon JA, Kingsberg SA, Portman D, et al.
Reference

Background reading on peptide chemistry and handling.